Darwin Global Management

Latest statistics and disclosures from Darwin Global Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are INSM, PCVX, GERN, KROS, SMMT, and represent 100.00% of Darwin Global Management's stock portfolio.
  • Added to shares of these 3 stocks: INSM (+$508M), SMMT (+$24M), PCVX (+$13M).
  • Started 1 new stock position in SMMT.
  • Reduced shares in these 7 stocks: CYTK (-$246M), CRBP (-$14M), SYRE (-$10M), GERN (-$8.5M), RNA (-$8.1M), ELEV, KROS.
  • Sold out of its positions in SYRE, RNA, CRBP, CYTK, ELEV.
  • Darwin Global Management was a net buyer of stock by $253M.
  • Darwin Global Management has $1.2B in assets under management (AUM), dropping by 43.09%.
  • Central Index Key (CIK): 0001839209

Tip: Access up to 7 years of quarterly data

Positions held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Darwin Global Management

Darwin Global Management holds 5 positions in its portfolio as reported in the September 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Insmed Com Par $.01 (INSM) 62.3 $766M +196% 11M 73.00
 View chart
Vaxcyte (PCVX) 20.4 $251M +5% 2.2M 114.27
 View chart
Geron Corporation (GERN) 8.1 $100M -7% 22M 4.54
 View chart
Keros Therapeutics (KROS) 7.2 $89M 1.5M 58.07
 View chart
Summit Therapeutics (SMMT) 1.9 $24M NEW 1.1M 21.90
 View chart

Past Filings by Darwin Global Management

SEC 13F filings are viewable for Darwin Global Management going back to 2020